Search
for
Sort by
Research 30 of 1000+
- Alopecia and hair repigmentation associated with anti-programmed death-ligand 1 (PD-L1) immunotherapy
- LB1681 Risk of merkel cell carcinoma progression after treatment discontinuation in patients with an objective response to anti-PD-(L)1 immunotherapy
- Anti-programmed cell death protein 1-induced lichenoid changes of the nail unit: Histopathologic description
- Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
- Age-associated inflammation connects RAS-induced senescence to stem cell dysfunction and epidermal malignancy
- Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
- N6-methyladenosine RNA Methylation Correlates with Immune Microenvironment and Immunotherapy Response of Melanoma
- Role of the SOX family in cancer immune evasion: Emerging player and promising therapeutic opportunities
- Global trends in tertiary lymphoid structures: a bibliometric analysis from 2014 to 2023
- 183 PD-1 regulatory network is upregulated in contact immunotherapy during alopecia areata treatment
- UTMD Enhances Targeting of Diclofenac and Doxil® to Boost Tumor Immunotherapy
- Toll-like receptor-targeted anti-tumor therapies: Advances and challenges
- Tregs: Where We Are and What Comes Next?
- What's new in the pathogeneses and triggering factors of bullous pemphigoid
- Management of Toxicities of Targeted Therapies
- The vitamin B5/coenzyme A axis: A target for immunomodulation?
- Targeted protein degradation of Wnt/β-catenin signaling pathway: an effective strategy for cancer therapy
- Repigmentation and new growth of hairs after anti–interleukin-17 therapy with secukinumab for psoriasis
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Immune Microenvironment of Hair Follicles in Tumor Immunotherapy
- A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Exploring the Drug Repurposing Versatility of Valproic Acid as a Multifunctional Regulator of Innate and Adaptive Immune Cells
- Comparative Analysis of Plant Exosomes and Human-Derived Exosomes: Structural Differences and Emerging Applications
- Anais do II Congresso Nacional Acadêmico de Dermatologia
- TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia
- ES01.01 Chemotherapy is Strictly Additive to Immunotherapy
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- Cellular therapeutics and immunotherapies in wound healing – on the pulse of time?
- Resolution of advanced conjunctival squamous cell carcinoma with cemiplimab immunotherapy, IFNα-2b, and retinoic acid treatment over 2 years of follow-up